Efficacy of Sacubitril/Valsartan in Treating Hemodialysis Patients with Reduced Ejection Fraction Heart Failure: A Retrospective Study
DOI:
https://doi.org/10.61882/ijkd.19.04.8743Keywords:
Sacubitril/valsartan, Heart failure with reduced ejection fraction, Maintenance hemodialysis, Chronic heart failure, Neprilysin inhibitor, Angiotensin receptor-neprilysin inhibitorAbstract
Introduction. Heart failure with reduced ejection fraction (HFrEF) is a prevalent and challenging complication among patients undergoing hemodialysis. Sacubitril/Valsartan (Sac-Val), an angiotensin receptor-neprilysin inhibitor, has shown promise in improving cardiac outcomes in HFrEF patients. This study aims to evaluate the efficacy and safety of Sac-Val in treating HFrEF in patients undergoing hemodialysis.
Methods. This retrospective analysis was conducted on 30 patients with HFrEF undergoing regular hemodialysis at Beijing Shijingshan Hospital between January 2019 and January 2023. The patients were divided into two groups: the Sac-Val group (14 patients) and the control group (16 patients). The Sac-Val group received an initial dose of 50 mg, titrated over four weeks to a maximum tolerated dose of 100 mg, while the control group received conventional heart failure treatment without Sac-Val. Both groups continued regular hemodialysis three times weekly. Statistical analysis included independent t-tests or Mann–Whitney U tests for continuous variables, and chi-square or Fisher’s exact tests for categorical variables. Heart failure improvements, blood pressure, NT-proBNP levels, biochemical markers, and echocardiographic changes were assessed after one year.
Results. The Sac-Val group showed significant improvements in systolic blood pressure (P = .027), NT-proBNP levels (P < .05), left ventricular ejection fraction (LVEF) (P < .04) compared to the control group. The Sac-Val group also had a higher total effective rate (85.71%) in alleviating heart failure symptoms compared to the control group (69%, P = .023).
Conclusion. Sac-Val is a safe and effective treatment for HFrEF patients undergoing hemodialysis, potentially improving their quality of life, heart function and clinical outcomes.
Downloads
References
1. Antlanger M, Aschauer S, Kopecky C, Hecking M, Kovarik JJ, Werzowa J, et al. Heart Failure with Preserved and Reduced Ejection Fraction in Hemodialysis Patients: Prevalence, Disease Prediction and Prognosis. Kidney and Blood Pressure Research. 11 aprile 2017;42(1):165–76.
2. Zhao X, Niu Q, Gan L, Hou FF, Liang X, Ni Z, et al. Thrombocytopenia predicts mortality in Chinese hemodialysis patients- an analysis of the China DOPPS. BMC Nephrol. 3 gennaio 2022;23:11.
3. Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol. 1 marzo 2000;35(3):681–9.
4. Chazot C, Jean G. The advantages and challenges of increasing the duration and frequency of maintenance dialysis sessions. Nat Clin Pract Nephrol. gennaio 2009;5(1):34–44.
5. Rangaswami J, McCullough PA. Heart Failure in End-Stage Kidney Disease: Pathophysiology, Diagnosis, and Therapeutic Strategies. Semin Nephrol. novembre 2018;38(6):600–17.
6. Gu J, Noe A, Chandra P, Al-Fayoumi S, Ligueros-Saylan M, Sarangapani R, et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol. aprile 2010;50(4):401–14.
7. Havakuk O, Elkayam U. Angiotensin Receptor-Neprilysin Inhibition. J Cardiovasc Pharmacol Ther. luglio 2017;22(4):356–64.
8. Mustafa NH, Jalil J, Zainalabidin S, Saleh MSM, Asmadi AY, Kamisah Y. Molecular mechanisms of sacubitril/valsartan in cardiac remodeling. Front Pharmacol [Internet]. 8 agosto 2022 [citato 28 agosto 2025];13. Disponibile su: https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.892460/full
9. Chioncel O, Lainscak M, Seferovic PM, Anker SD, Crespo-Leiro MG, Harjola VP, et al. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. European Journal of Heart Failure. 2017;19(12):1574–85.
10. Niu C, Yang S, Ou S, Wu C, Huang P, Hung C, et al. Sacubitril/Valsartan in Patients With Heart Failure and Concomitant End‐Stage Kidney Disease. Journal of the American Heart Association. 20 settembre 2022;11(18):e026407.
11. Feng Z, Wang X, Zhang L, Apaer R, Xu L, Ma J, et al. Pharmacokinetics and Pharmacodynamics of Sacubitril/Valsartan in Maintenance Hemodialysis Patients with Heart Failure. Blood Purification. 9 novembre 2021;51(3):270–9.
12. Lee S, Oh J, Kim H, Ha J, Chun K hyeon, Lee CJ, et al. Sacubitril/valsartan in patients with heart failure with reduced ejection fraction with end-stage of renal disease. ESC Heart Failure. 2020;7(3):1125–9.
13. Raphael DM, Liu Z, Jin Z, Cui X, Han D, He W, et al. Effects of sacubitril/valsartan on clinical symptoms, echocardiographic parameters, and outcomes in HFrEF and HFmrEF patients with coronary heart disease and chronic kidney disease. Current Medical Research and Opinion. 3 luglio 2021;37(7):1071–8.
14. Lee WC, Liao TW, Chen TY, Fang HY, Fang YN, Chen HC, et al. Sacubitril/valsartan improves all-cause mortality in heart failure patients with reduced ejection fraction and chronic kidney disease. Cardiovasc Drugs Ther. 1 giugno 2024;38(3):505–15.
15. Mohebi R, Liu Y, Pi ña IL, Prescott MF, Butler J, Felker GM, et al. Dose-Response to Sacubitril/Valsartan in Patients With Heart Failure and Reduced Ejection Fraction. Journal of the American College of Cardiology. 18 ottobre 2022;80(16):1529–41.
16. Vardeny O, Claggett B, Packer M, Zile MR, Rouleau J, Swedberg K, et al. Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial. Eur J Heart Fail. ottobre 2016;18(10):1228–34.
17. Nguyen DV, Le TN, Truong BQ, Nguyen HTT. Efficacy and safety of angiotensin receptor-neprilysin inhibition in heart failure patients with end-stage kidney disease on maintenance dialysis: A systematic review and meta-analysis. Eur J Heart Fail. gennaio 2025;27(1):72–84.
18. Proudfoot C, Studer R, Rajput T, Jindal R, Agrawal R, Corda S, et al. Real-world effectiveness and safety of sacubitril/valsartan in heart failure: A systematic review. Int J Cardiol. 15 maggio 2021;331:164–71.
19. Le D, Grams ME, Coresh J, Shin JI. Sacubitril-Valsartan in Patients Requiring Hemodialysis. JAMA Network Open. 20 agosto 2024;7(8):e2429237.
20. White PD, Myers M. The classification of cardiac diagnosis. JAMA. 1921;77(18):1414–5.
21. Bredy C, Ministeri M, Kempny A, Alonso-Gonzalez R, Swan L, Uebing A, et al. New York Heart Association (NYHA) classification in adults with congenital heart disease: relation to objective measures of exercise and outcome. European Heart Journal - Quality of Care and Clinical Outcomes. 1 gennaio 2018;4(1):51–8.
22. Lutsey PL, Alonso A, Michos ED, Loehr LR, Astor BC, Coresh J, et al. Serum magnesium, phosphorus, and calcium are associated with risk of incident heart failure: the Atherosclerosis Risk in Communities (ARIC) Study123. Am J Clin Nutr. settembre 2014;100(3):756–64.
23. Nicolas D, Patel P, Reed M. Sacubitril-Valsartan. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 [citato 28 agosto 2025]. Disponibile su: http://www.ncbi.nlm.nih.gov/books/NBK507904/
24. Yoshioka G, Tanaka A, Goriki Y, Node K. The role of albumin level in cardiovascular disease: a review of recent research advances. Journal of Laboratory and Precision Medicine [Internet]. 30 gennaio 2023 [citato 4 agosto 2024];8(0). Disponibile su: https://jlpm.amegroups.org/article/view/7523
25. Gottlieb SS, Baruch L, Kukin ML, Bernstein JL, Fisher ML, Packer M. Prognostic importance of the serum magnesium concentration in patients with congestive heart failure. Journal of the American College of Cardiology. 1 ottobre 1990;16(4):827–31.
26. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. [citato 28 agosto 2025]; Disponibile su: https://onlinelibrary.wiley.com/doi/10.1002/ejhf.2333
27. Pascual -Figal Domingo, Wachter R, Senni M, Bao W, No è A, Schwende H, et al. NT-proBNP Response to Sacubitril/Valsartan in Hospitalized Heart Failure Patients With Reduced Ejection Fraction. JACC: Heart Failure. ottobre 2020;8(10):822–33.
28. Myhre PL, Prescott MF, Murphy SP, Fang JC, Mitchell GF, Ward JH, et al. Early B-Type Natriuretic Peptide Change in HFrEF Patients Treated With Sacubitril/Valsartan. JACC: Heart Failure. febbraio 2022;10(2):119–28.
29. Bressendorff I, Hansen D, Schou M, Pasch A, Brandi L. The Effect of Increasing Dialysate Magnesium on Serum Calcification Propensity in Subjects with End Stage Kidney Disease. Clin J Am Soc Nephrol. 7 settembre 2018;13(9):1373–80.
